logo

RCUS

Arcus Biosciences·NYSE
--
--(--)
--
--(--)
3.00 / 10
Underperform

RCUS scores only 3.0 out of 10 on fundamental metrics, reflecting weak financial health. Key weaknesses include a low current assets turnover ratio (0.2285) and poor net profit margin (0.00%), while cash flow and inventory factors show marginal strength. Historical back-tests suggest limited upside potential, and the overall view is prudent due to these structural deficiencies.

Fundamental(3)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-2.00
Score1/3
Weight10.22%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.98%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight20.54%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight15.30%
1M Return7.79%
PB-ROE
Value0.43
Score1/3
Weight14.13%
1M Return7.02%
Current assets turnover ratio
Value0.23
Score0/3
Weight-2.80%
1M Return-1.88%
Fixed assets turnover ratio
Value4.81
Score2/3
Weight0.20%
1M Return0.12%
Asset-MV
Value-0.50
Score1/3
Weight18.55%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight15.32%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.45%
1M Return-0.30%
Is RCUS fundamentally strong?
  • RCUS scores 3.00/10 on fundamentals and holds a Premium valuation at present. Backed by its -53.64% ROE, -142.08% net margin, -7.50 P/E ratio, 5.87 P/B ratio, and -7.21% earnings growth, these metrics solidify its Underperform investment rating.